Minimizing the toxicity of antilymphocyte antibody therapy.
Pascual
M
M
Transplantation Unit, Massachusetts General Hospital, Boston 02114, USA.
Rubin
R H
RH
Cosimi
A B
AB
D000212:Acyclovir / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D003141:Communicable Diseases / Q000453:epidemiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016853:Muromonab-CD3 / Q000009:adverse effects; D011183:Postoperative Complications; D013577:Syndrome; D014181:Transplantation Immunology
D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D000212:Acyclovir